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Abstract: Unselected population-based personalised ovarian cancer (OC) risk assessment combining
genetic/epidemiology/hormonal data has not previously been undertaken. We aimed to perform
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a feasibility study of OC risk stratification of general population women using a personalised OC
risk tool followed by risk management. Volunteers were recruited through London primary care
networks. Inclusion criteria: women ≥18 years. Exclusion criteria: prior ovarian/tubal/peritoneal
cancer, previous genetic testing for OC genes. Participants accessed an online/web-based
decision aid along with optional telephone helpline use. Consenting individuals completed risk
assessment and underwent genetic testing (BRCA1/BRCA2/RAD51C/RAD51D/BRIP1, OC susceptibility
single-nucleotide polymorphisms). A validated OC risk prediction algorithm provided a personalised
OC risk estimate using genetic/lifestyle/hormonal OC risk factors. Population genetic testing
(PGT)/OC risk stratification uptake/acceptability, satisfaction, decision aid/telephone helpline use,
psychological health and quality of life were assessed using validated/customised questionnaires over
six months. Linear-mixed models/contrast tests analysed impact on study outcomes. Main outcomes:
feasibility/acceptability, uptake, decision aid/telephone helpline use, satisfaction/regret, and impact
on psychological health/quality of life. In total, 123 volunteers (mean age = 48.5 (SD = 15.4) years)
used the decision aid, 105 (85%) consented. None fulfilled NHS genetic testing clinical criteria.
OC risk stratification revealed 1/103 at ≥10% (high), 0/103 at ≥5%–<10% (intermediate), and 100/103
at <5% (low) lifetime OC risk. Decision aid satisfaction was 92.2%. The telephone helpline use rate
was 13% and the questionnaire response rate at six months was 75%. Contrast tests indicated that
overall depression (p = 0.30), anxiety (p = 0.10), quality-of-life (p = 0.99), and distress (p = 0.25) levels
did not jointly change, while OC worry (p = 0.021) and general cancer risk perception (p = 0.015)
decreased over six months. In total, 85.5–98.7% were satisfied with their decision. Findings suggest
population-based personalised OC risk stratification is feasible and acceptable, has high satisfaction,
reduces cancer worry/risk perception, and does not negatively impact psychological health/quality
of life.
Keywords: population genetic testing; ovarian cancer risk; risk stratification; BRCA1; BRCA2;
RAD51C; RAD51D; BRIP1; SNP; risk modelling
1. Introduction
BRCA1/BRCA2 pathogenic variants have a 17–44% ovarian cancer (OC) risk until age 80 years [1].
Testing for OC susceptibility genes (CSGs)—RAD51C (lifetime OC risk = 11%) [2], RAD51D (lifetime OC
risk = 13%) [2] and BRIP1 (lifetime OC risk = 5.8%) [3]—is now part of clinical practice. Genome-wide
association studies (GWAS) have discovered ~30 validated single-nucleotide polymorphisms (SNPs)
which modify OC risk [4,5]. Newer risk prediction models incorporating validated SNPs as a polygenic
risk score with epidemiologic/family history(FH)/hormonal data and moderate–high-penetrance CSGs
can be used to predict lifetime OC risk, improving the precision of risk estimation and allowing
population division into risk strata, enabling targeted downstream risk-stratified prevention/screening
for those at increased risk [4,6].
The current practice of identifying high-risk women uses clinical criteria/FH-based testing for
CSGs, misses >50% CSG carriers who do not fulfil genetic testing criteria and requires people to
get cancer before identifying unaffected family members who can benefit from prevention [7–10].
Given the effective cancer risk management/prevention options available, the adequacy of current
practice, representing massive missed opportunities for risk-stratified prevention, is questionable.
Unselected population genetic testing (PGT) overcomes these limitations and identifies many more
individuals at increased OC risk. PGT can be cost effective and prevent thousands of more OC/BC
cases than clinical criteria/FH-based genetic testing [11].
Most PGT evidence comes from UK/Israeli/Canadian studies in Ashkenazi Jewish (AJ)
populations [9,10,12]. These show that AJ population-based BRCA testing is acceptable, feasible,
can be community based, doubles the BRCA pathogenic variant individuals identified, does not
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harm psychological health/quality of life (QoL), reduces long-term anxiety, has high satisfaction
rates (90–95%) [9,10,13], and is extremely cost effective (potentially cost saving) for the UK/US health
systems [14]. However, prospective/unbiased PGT data and model-based OC risk stratification for a
general (non-Jewish) low-risk population are lacking.
We describe results from a feasibility study in order to stratify a general population using
predicted lifetime OC risk and offer risk management options of screening and prevention, within
the Predicting Risk of Ovarian Malignancy Improved Screening and Early detection programme
(PROMISE-FS, ISRCTN54246466). This article reports on (1) the acceptability, feasibility, and uptake of
PGT/OC risk stratification; (2) perceived risks/limitations; (3) decision aid (DA)/telephone helpline use;
(4) satisfaction; (5) cancer worry/risk perception; (6) impact on psychological health/QoL.
2. Results
Between June 2017 and August 2017, 218 women registered and 123 viewed the online DA. In total,
105/123 (85%) DA users consented to genetic testing/risk assessment, and two withdrew. In total,
103 were eligible for analysis (Figure 1). In total, 2/103 were excluded from RPA assessment (Figure 1).
Women who chose not to participate declined providing information on factors affecting decision
making. The follow-up questionnaire response rate was 94%, 84%, and 75% at seven days, three months
and six months post results, respectively.
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Table 1 summarises cohort baseline characteristics. The mean age of participants was 48.5
(SD = 15.4; range = 18–85) years; 44.6% (n = 45) had university level education; 55.7% (n = 54)
had a household income >£40,000; 74.5% (n = 76) were Caucasian; 7% (n = 7) were smokers;
64% (n = 63) ate >5 portions of fruit/vegetables daily; 78% (n = 80) were physically active over
the last month. None had a clinically significant FH of cancer (fulfilling NHS genetic testing
criteria). RPA revealed 1/103 at ≥10%, 0/103 at ≥5%–<10% and 100/103 at <5% lifetime OC risk.
As expected using the algorithm, the epidemiological risk factors alone provide a greater level
of OC risk stratification among the participants compared to the polygenic risk score (PRS) alone
(Figure S1). However, risk stratification is further improved when the full model incorporating
both epidemiological risk factors and PRS is considered. One high-risk participant, aged 35 years,
had a lifetime OC risk of 42%. She had a pathogenic duplication of exon-13 in BRCA1. History
included one second-degree relative with OC—parity = 1, 10 years oral contraceptive pill (OCP)
use, endometriosis, BMI = 30.4, and no tubal ligation/hormone-replacement therapy (HRT) use.
Following results, the participant opted for Risk of Ovarian Cancer Algorithm (ROCA)-based screening
(24) within a research study (ALDO, https://www.uclh.nhs.uk/OurServices/ServiceA-Z/Cancer/NC
V/Pages/TheALDOproject.aspx) and for risk-reducing early salpingectomy within a clinical trial
(PROTECTOR, ISRCTN25173360, http://www.protector.org.uk/). She underwent MRI screening for BC
risk. Four Class-3 variants of uncertain significance (VUS) were detected (BRCA1:c.3328_3330delAAG,
c.2998_3003del; BRCA2:c.1438T>G; RAD51D:c.482T>C).
Table 1. Baseline characteristics of cohort.
Characteristic % N
Mean age, years (SD, range) 48.54 (15.42, 18–85)
Marital status
Single 20 20/100
Married 52 52/100
Cohabiting/living with partner 15 15/100
Divorced/separated 11 11/100
Widowed 2 2/100
Children
Have children 65.69 67/102
Mean number of children (SD, range) 1.34 (1.23, 0–5)
Education
No formal qualification 5.94 6/101
GCSE/O-level/CSE 17.82 18/101
NVQ1/NVQ2 0.99 1/101
A-level/NVQ3 26.73 27/101
NVQ4 3.96 4/101
Bachelors 26.73 27/101
Masters 13.86 14/101
PhD 3.96 4/101
Income (£)
<10,000 13.4 13/97
10,000–19,000 7.22 7/97
20,000–29,000 13.4 13/97
30,000–39,900 10.31 10/97
40,000–49,900 11.34 11/97
>50,000 44.33 43/97
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Table 1. Cont.
Characteristic % N
Ethnicity
White 74.51 76/102
Asian 13.73 14/102
Black/Afro-Caribbean 2.94 3/102
Mixed 6.86 7/102
Other 1.96 2/102
Religion
Christian 59.41 60/101
Muslim 6.93 7/101
Jewish 4.95 5/101
Buddhist 0.99 1/101
Hindu 1.98 2/101
Sikh 1.98 2/101
No religion 22.77 23/101
Other 0.99 1/101
FH/clinical criteria positive 0 0/102
FH of cancer
Total number of participants with any FH of ovarian cancer 11.76 12/102
Number of participants with a FDR with ovarian cancer 5.88 6/102
Number of participants with a SDR with ovarian cancer 5.88 6/102
Number of participants with a TDR with ovarian cancer 0 0/102
Total number of participants with any FH of breast cancer 44.12 45/102
Number of participants with a FDR with breast cancer 14.71 15/102
Number of participants with a SDR with breast cancer 23.53 24/102
Number of participants with a TDR with breast cancer 5.88 6/102
Total number of participants with a FH of breast and ovarian cancer 0.98 1/102
Total number of participants with any FH of prostate cancer 17.65 18/102
Number of participants with a FDR with prostate cancer 7.84 8/102
Number of participants with a SDR with prostate cancer 7.84 8/102
Number of participants with a TDR with prostate cancer 1.96 2/102
Total number of participants with any FH of pancreatic cancer 4.9 5/102
Number of participants with a FDR with pancreatic cancer 0.00 0/102
Number of participants with a SDR with pancreatic cancer 3.92 4/102
Number of participants with a TDR with pancreatic cancer 0.98 1/102
Psychiatric history
Depression 9 9/100
Other psychiatric condition 5 5/100
Current medication for psychiatric condition 5 5/100
Personal history of non-ovarian cancer
Breast cancer 0 0/102
Other cancers 3.92 4/102
Previous genetic testing unrelated to HBOC 1.98 2/101
Breast self-examination in the last 12 months
Never 29.41 30/102
<once a month 48.04 49/102
once a month 14.71 15/102
>once a month 7.84 8/102
Clinical screening for breast cancer
Ever had a clinical breast exam 56.57 56/99
Ever had a MRI 4 4/100
Ever had a mammogram 54.46 55/101
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Table 1. Cont.
Characteristic % N
Ovarian cancer screening
Currently undergoing screening 1.96 2/102
Have previously undergone screening 11.11 11/99
Previous surgical prevention to prevent ovarian cancer 0 0/102
Health behaviour and lifestyle
Smoking
Ever smokers 25.49 26/102
Current smokers 7.07 7/99
Alcohol consumption in the past 12 months
Every week 48.04 49/102
Every month 14.71 15/102
Less frequently than once a month 21.57 22/102
Not at all 15.69 16/102
Median alcohol consumption on a typical day in units (IQR) 2 (1–2)
≥5 portions of fruit and vegetables 63.64 63/99
Number of participants who consume red meat 81.37 83/102
Number of participants currently using vitamin supplements 51.51 51/99
Physical exercise (past month) 78.43 80/102
Risk prediction algorithm results
High lifetime ovarian cancer risk 0.97 1/103
Intermediate ovarian cancer risk 0 0/103
Low lifetime ovarian cancer risk 97.09 100/103
Excluded * 1.94 2/103
Mean lifetime risk prediction score (excluding the high-risk
participant (SD, range)) 1.39 (0.69, 0.56–4.38)
Mean lifetime risk prediction score (including the high-risk
participant (SD, range)) 1.80 (4.10, 0.56–41.98)
FH: family history; FDR: first-degree relative; SDR: second-degree relative; TDR: third-degree relative;
HBOC: hereditary breast and ovarian cancer; SD: standard deviation. * One participant was excluded because she
entered this study at age 84 and the model predicts risks to age 80. A second participant was excluded because she
did not provide any baseline demographic information. Both participants were provided with their high-penetrance
gene results, but personalised risk scores were not provided.
Key perceived benefits/risks of PGT/OC risk assessment are shown in Table S1. Need for reassurance,
reduction in uncertainty, enhancing cancer prevention, benefiting research, knowledge about enhanced
screening/prevention and children’s risks were rated somewhat/very important by ~70–98% women.
Important risks/limitations of PGT/OC risk assessment rated somewhat/very important included concern
about effect on family (56.4%) and being unable to handle it emotionally (38.6%). A minority felt
stigmatization (9%) or targeting of an ethnic group (11%) was a somewhat/very important risk.
Insurance and confidentiality were highlighted as somewhat/very important by 28% and 24.7% respectively.
Participant responses to the ten DA items are shown in Table S2. The mean number of times
DA was viewed was non-significantly higher in consenters versus decliners (1.61 vs. 1.05; p = 0.06).
The mean DA score was not significantly different between consenters and decliners (8.1 vs. 7.4;
p = 0.14). Consenters were older than decliners (48.5 vs. 40, p = 0.016). The mean age of volunteers
who registered but did not view the DA was 45.5 years and not significantly different from consenters
(p = 0.16) or decliners (p = 0.24). There was no statistically significant difference in 9/10 DA item
responses between consenters and decliners. (Table S2). In total, 88.3% of consenters versus 75%
of decliners (p = 0.036) would regret not participating if they developed OC in the future. In total,
23/123 viewed the DA on multiple occasions, and DA scores increased on repeat attempts (Tables S3
and S4). For 122/123 participants, there was concordance between participant decision making and
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DA outcome category. One participant (85 years, Caucasian, no OC-FH) consented to PGT/OC risk
stratification despite DA advice to the contrary (DA score = −1). Table 2 summarises responses to the
DA evaluation questionnaire. In total, 92.2% (94/102) were very satisfied/satisfied and 82.2% (83/101)
would recommend the DA. The amount of information provided, length of time taken to view and
level of detail available was deemed just right by 98% (100/102), 97.1% (99/102), and 97% (98/101),
respectively. No part of the DA needed omitting.
Table 2. Decision aid evaluation questionnaire responses.
Satisfaction % N
Very satisfied 47.06 48/102
Satisfied 45.1 46/102
Neither satisfied nor dissatisfied 5.88 6/102
Dissatisfied 0.98 1/102
Very dissatisfied 0.98 1/102
Amount of information provided
Too little 1.96 2/102
About right 98.04 100/102
Too much 0 0/102
Length of time taken to view DA
Too short 0 0/102
About right 97.06 99/102
Too long 2.94 3/102
Do any parts of the DA require more detail?
Yes 2.97 3/101
No 97.03 98/101
Are there any parts of the DA that should be
left out?
Yes 0 0/99
No 100 99/99
Would you recommend DA use?
Yes 82.18 83/101
No 0.99 1/101
Not sure 16.83 17/101
How much the DA improved
understanding of:
Not at all Not very much Somewhat Quite a bit A lot
% N % N % N % N % N
OC 7.92 8/101 12.87 13/101 34.65 35/101 28.71 29/101 15.84 16/101
Disadvantages of discovering
OC risk (%) 3.96 4/101 6.93 7/101 40.59 41/101 28.71 29/101 19.8 20/101
Advantages of discovering
OC risk 2.97 3/101 7.92 8/101 26.73 27/101 36.63 37/101 25.74 26/101
Genetic testing for OC genes 1.98 2/101 8.91 9/101 29.7 30/101 33.66 34/101 25.74 26/101
Implications of carrying OC
gene alteration 3.96 4/101 5.94 6/101 36.63 37/101 28.71 29/101 24.75 25/101
Emotional response to DA
Worried/concerned 56.44 57/101 27.72 28/101 13.86 14/101 1.98 2/101 0 0/101
Reassured 6.86 7/102 12.75 13/102 35.29 36/102 25.49 26/102 19.61 20/102
Upset 80.2 81/101 14.85 15/101 3.96 4/101 0 0/101 0.99 1/101
In total, 13% (13/103) of consenters used the optional telephone helpline (Table 3), and 8/13 filled
in an evaluation questionnaire. No decliner used the telephone helpline. The mean number of calls
to the telephone helpline was 1.38 (SD = 1.12; range = 1–5). In total, 12.5% (1/8) used the telephone
helpline to aid decision making and 75% (6/8) had study specific queries—of which, DA technical
assistance queries (4/8) were the most common. All helpline users were very satisfied/satisfied with
their experience and 75% (6/8) would recommend the helpline. In total, 37.5% (3/8) felt that the
helpline aided decision making. There was no difference in baseline characteristics between helpline
users and non-users. When comparing how much the DA improved understanding of OC/gene
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testing/advantages and disadvantages of discovering personalised OC risk or DA satisfaction, there
was no statistically significant difference between helpline users/non-users. Helpline users had a
significantly greater degree of worry (2/13 vs. 0/89; p = 0.02) and upset (1/13 vs. 0/89; p = 0.003)
when viewing the DA in comparison to non-users. Helpline users had a higher DA mean score than
non-users (9.123 vs. 8.019; p = 0.032)
Table 3. Telephone helpline evaluation questionnaire responses.
Telephone Helpline Evaluation Questionnaire % N
Total number of women using the helpline 12.62 13/103
Number of participants using helpline who consented to this study 100 13/13
Mean number of times used (SD, range) 1.38 (1.12, 1–5)
Reason for helpline use
To help decide whether to take part in this study 12.5 1/8
To ask a study specific question not related to decision making 75 6/8
Technical assistance with the decision aid 50 4/8
Pregnancy related query 25 2/8
Results query 12.5 1/8
Satisfaction with helpline
Very satisfied 75 6/8
Satisfied 25 2/8
Neither satisfied nor dissatisfied 0 0/8
Dissatisfied 0 0/8
Very dissatisfied 0 0/8
Did the helpline help with decision making?
Yes 37.5 3/8
No 50 4/8
Not sure 12.5 1/8
Would you recommend helpline use?
Yes 75 6/8
No 0 0/8
Not sure 25 2/8
SD: standard deviation; 8/13 participants who used the telephone helpline completed the telephone helpline
questionnaire. Data are presented for these eight participants.
Mean Hospital Anxiety and Depression Scale (HADS)/EuroQol-5D-5L (EQ-5D-5L)/Impact of
Events Scale (IES)/Cancer Risk Perception questionnaire (CRP)/Cancer Worry Scale questionnaire
(CWS)/Decision Regret Satisfaction questionnaire (DRS) questionnaire scores at baseline and at seven
days/three months/six months follow up are shown in Table 4.
Table 4. Mean questionnaire scores at baseline and at seven days, three months and six months
follow up.
Validated
Questionnaire Baseline
7 Days Post
Results
3 Months Post
Results
6 Months Post
Results
HADS
Total 9.06 (SD = 6.11,range 0–23)
10.43 (SD = 6.26,
range 0–30)
9.78 (SD = 7.1,
range 0–31)
9.64 (SD = 7.06,
range 0–28)
Anxiety 6.11 (SD = 4.05,range 0–17)
7.02 (SD = 4.02,
range 0–18)
6.35 (SD = 3.97,
range 0–16)
6.1 (SD = 4.06,
range 0–15)
Depression 2.92 (SD = 2.9,range 0–11)
3.41 (SD = 3.07,
range 0–14)
3.36 (SD = 3.71,
range 0–16)
3.55 (SD = 3.62,
range 0–14)
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Table 4. Cont.
Validated
Questionnaire Baseline
7 Days Post
Results
3 Months Post
Results
6 Months Post
Results
EQ-5D-5L
Total 0.86 (SD = 0.14,range 0.382–1)
0.84 (SD = 0.17,
range 0.259–1)
0.83 (SD = 0.21,
range 0.051–1)
0.84 (SD = 0.17,
range –0.035–1)
VAS 81.27 (SD = 13.9,range 35–100)
80.61 (SD = 16.11,
range 4–100)
80.45 (SD = 18.81,
range 15–100)
80.76 (SD = 15.3,
range 20–100)
Mobility 1.25 (SD = 0.57,range 1–3)
1.26 (SD = 0.55,
range 1–3)
1.35 (SD = 0.8,
range 1–5)
1.47 (SD = 0.92,
range 1–5)
Self-care 1.08 (SD = 0.39,range 1–4)
1.04 (SD = 0.2,
range 1–2)
1.12 (SD = 0.57,
range 1–5)
1.21 (SD = 0.82,
range 1–5)
Usual activities 1.25 (SD = 0.57,range 1–4)
1.24 (SD = 0.52,
range 1–3)
1.38 (SD = 0.77,
range 1–5)
1.42 (SD = 0.94,
range 1–5)
Pain/discomfort 1.55 (SD = 0.71,range 1–4)
1.65 (SD = 0.8,
range 1–4)
1.68 (SD = 0.95,
range 1–5)
1.71 (SD = 0.82,
range 1–5)
Anxiety/depression 1.43 (SD = 0.69,range 1–4)
1.58 (SD = 0.88,
range 1–5)
1.58 (SD = 0.88,
range 1–5)
1.53 (SD = 0.71,
range 1–3)
IES 7.93 (SD = 15.06,range 0–67)
7.57 (SD = 17.07,
range 0–73)
4.95 (SD = 10.61,
range 0–48)
CWS 5.8 (SD = 1.96,range 4–14)
5.13 (SD = 1.61,
range 4–12)
5.04 (SD = 1.51,
range 4–11)
5.17 (SD = 1.61,
range 4–11)
CRP
CRP Likert scale 2.93 (SD = 0.78,range 1–5)
2.72 (SD = 0.83,
range 1–5)
2.86 (SD = 0.66,
range 1–5)
2.93 (SD = 0.74,
range 1–5)
CRP VAS 46.05 (SD = 22.1,range 0–90)
44.51 (SD = 24.61,
range 2–90)
47.43 (SD = 21.81,
range 0–90)
49.67 (SD = 22.84,
1–90)
DRS
DRS scale 27 (SD = 52.11,range 0–250)
DRS Madalinska 1.16 (SD = 0.4,range 1–3)
HADS: Hospital Anxiety and Depression Scale questionnaire; IES: Impact of Events Scale questionnaire; CRP: Cancer
Risk Perception questionnaire; CWS: Cancer Worry Scale questionnaire; DRS: Decision Regret Satisfaction
questionnaire; VAS: Visual Analogue Scale. HADS: 14 item questionnaire, with 7 items pertaining to anxiety and 7 to
depression. Each item is scored on a 4-point Likert scale, from 0 to 3, with total scores ranging from 0 to 42. Higher
scores indicate higher levels of anxiety/depression. EQ-5D-5L: EuroQol-5D-5L 5 item questionnaire. Each item
(mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) is scored on a 5-point Likert scale,
from 1 to 5. Higher scores indicate poorer health. Total scores are then converted into a utility value using published
reference values for the UK by the EuroQol Research Foundation. Utility values range from 0 to 1, with 0 indicating
the worst health and 1 the best health. In addition, participants are asked to state “how good or bad your health is
today” using a Visual Analogue Scale ranging from 0 (worst health) to 100 (best health). IES: 15 item questionnaire.
Each item is scored on a 4-point Likert scale, from 0 to 5, with total scores ranging from 0 to 75. Higher scores
indicate higher distress levels. CWS: 4 item questionnaire. Each item is scored on a 4-point Likert scale, from 1
to 4, with total scores ranging from 4 to 16. Higher scores indicate greater worry of developing ovarian cancer.
CRP: 1 item questionnaire. The item is scored on a 5-point Likert scale, from 1 to 5. A higher score indicates that
the individual perceives that they are at greater risk of developing cancer of any type at some point in their life
compared to other women of the same age. In addition, participants are asked to state “on a scale from 0 to 100,
where 0 is no chance at all, and 100 is absolutely certain, what do you think are the chances that you will get cancer
(of any type) sometime during your lifetime?” DRS: First part consists of a 5 item questionnaire (Decision Satisfaction
Regret Scale. Each item is scored on a 5-point Likert scale, from 0 to 100, with total scores ranging from 0 to 500.
Higher scores indicate less satisfaction/more regret. Second part consists of a 1 item questionnaire (Madalinska).
The item is scored on a 5-point Likert scale, from 0 to 100. Higher scores indicate less satisfaction/more regret.
Linear random-effects mixed-model outputs showing the association of covariates with different
outcomes are shown in Table 5. There was a transient increase in HADS anxiety at seven days
(p = 0.048), returning to baseline by three months (p = 0.318). Compared to baseline, there was a
small increase in HADS depression scores at individual time points of 3 months (p = 0.027) and
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6 months (p ≤ 0.001), while QoL scores were marginally lower at three (p = 0.025) and six months
(p = 0.036). However, the absolute level of change from baseline in all these scores was extremely
small (HADS depression = 2.92 to 3.55; HADS anxiety = 6.11 to 7.02; EQ-5D-5L = 0.86 to 0.84) and not
clinically meaningful. Additionally, contrast tests evaluating whether overall mean values at seven
days, three months and six months were jointly different from the baseline suggested that anxiety,
depression and QoL at these time points were not jointly different from the baseline value for the
cohort (Table 5). Distress scores decreased with time and were significantly lower at six months versus
7 days (p = 0.042). Compared to baseline, OC worry was significantly lower at 7 days (p ≤ 0.001),
3 months (p ≤ 0.001) and 6 months (p ≤ 0.001). Contrast tests evaluating the overall time effect showed
a significant decrease in OC worry scores (p = 0.02) but not distress scores (p = 0.25) over time (Table 5).
General cancer risk perception showed a decrease at 7 days (p = 0.012), returning to baseline by
6 months (p = 0.45).
Table 5. Linear random-effects mixed models and overall contrast tests for study outcomes.
Model and Variable Coef. Std. Err p > |z| 95% CI
HADS Total
FH Breast Cancer 1.66 1.334 0.217 −0.782 to 4.3
FH Ovarian Cancer 0.426 2.146 0.843 −3.766 to 4.616
* 7 Days 1.068 0.513 0.039 0.159 to 2.071
3 Months 0.986 0.537 0.068 −0.094 to 2.148
* 6 Months 1.268 0.557 0.024 0.215 to 2.385
Age −0.015 0.046 0.742 −0.101 to 0.078
Income −0.633 0.411 0.127 −1.452 to 0.178
Marital Status 1.321 1.424 0.356 −1.608 to 4.675
Ethnicity 3.349 1.899 0.081 −0.716 to 7.141
Religion: Jewish −1.715 3.116 0.584 −7.559 to 4.456
Religion: Muslim −6.223 3.228 0.057 −12.655 to 0.751
Religion: Atheist −0.736 1.582 0.643 −3.893 to 2.478
Religion: Other −3.759 2.848 0.19 −9.587 to 2.509
HADS Total df Chi-sq p-value
# BL vs. Overall (joint) 3 5.2 0.158
HADS Anxiety
FH Breast Cancer 0.933 0.801 0.248 −0.63 to 2.625
FH Ovarian Cancer −0.142 1.285 0.912 −2.552 to 2.373
* 7 Days 0.649 0.326 0.048 0.006 to 1.278
3 Months 0.339 0.339 0.318 −0.377 to 1.022
6 Months 0.172 0.353 0.628 −0.498 to 0.88
Age −0.026 0.028 0.346 −0.083 to 0.028
Income −0.216 0.247 0.383 −0.66 to 0.255
Marital Status 0.505 0.856 0.557 −1.285 to 2.123
Ethnicity 1.688 1.143 0.143 −0.433 to 3.799
Religion: Jewish 0.039 1.871 0.984 −3.838 to 3.558
* Religion: Muslim −4.136 1.941 0.036 −7.79 to −0.387
Religion: Atheist −0.89 0.951 0.352 −2.71 to 1.051
Religion: Other −1.975 1.707 0.251 −5.541 to 1.271
HADS Anxiety df Chi-sq p-value
# BL vs. Overall (joint) 3 6.22 0.102
HADS Depression
FH Breast Cancer 0.778 0.655 0.238 −0.55 to 2.141
FH Ovarian Cancer 0.942 1.086 0.387 −1.201 to 3.16
7 Days 0.481 0.292 0.101 −0.03 to 1.048
* 3 Months 0.68 0.304 0.027 0.062 to 1.257
* 6 Months 1.155 0.317 <0.001 0.54 to 1.772
Age 0.012 0.022 0.586 −0.033 to 0.054
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* Income −0.403 0.2 0.047 −0.805 to −0.031
Marital Status 0.8 0.702 0.258 −0.579 to 2.132
Ethnicity 1.642 0.925 0.079 −0.249 to 3.377
Religion: Jewish −1.782 1.53 0.248 −5.021 to 1.214
Religion: Muslim −1.996 1.562 0.205 −5.08 to 1.209
Religion: Atheist 0.148 0.776 0.85 −1.312 to 1.787
Religion: Other −1.769 1.388 0.206 −4.607 to 1.095
HADS Depression df Chi-sq p-value
# BL vs. Overall (joint) 3 3.7 0.296
EQ-5D-5L Total
FH Breast Cancer −0.068 0.031 0.034 −0.135 to −0.008
FH Ovarian Cancer −0.066 0.052 0.204 −0.171 to 0.028
7 Days −0.026 0.015 0.082 −0.056 to 0.003
* 3 Months −0.034 0.015 0.025 −0.062 to −0.004
6 Months −0.033 0.016 0.036 −0.069 to −0.005
Age −0.002 0.001 0.138 −0.004 to 0.001
Income 0.013 0.01 0.19 −0.007 to 0.032
Marital Status −0.01 0.034 0.756 −0.076 to 0.061
Ethnicity −0.05 0.044 0.262 −0.136 to 0.038
Religion: Jewish −0.011 0.073 0.885 −0.155 to 0.136
Religion: Muslim 0.059 0.075 0.435 −0.106 to 0.209
Religion: Atheist 0.058 0.037 0.12 −0.012 to 0.136
Religion: Other 0.078 0.066 0.242 −0.058 to 0.202
EQ-5D-5L Total df Chi-sq p-value
# BL vs. Overall (joint) 3 0.14 0.987
EQ-5D-5L VAS
FH Breast Cancer −4.74 2.792 0.093 −10.024 to 0.915
FH Ovarian Cancer −6.613 4.908 0.18 −16.246 to 3.636
7 Days −1.537 1.68 0.361 −5.063 to 2.159
3 Months −3.244 1.749 0.065 −6.533 to 0.491
6 Months −2.492 1.798 0.167 −6.161 to 1.046
Age 0.048 0.097 0.621 −0.143 to 0.243
* Income 1.819 0.859 0.037 0.267 to 3.524
Marital Status −0.386 2.997 0.898 −6.607 to 5.465
Ethnicity −7.129 4.004 0.078 −15.297 to −0.015
Religion: Jewish −1.73 6.474 0.79 −14.671 to 10.225
Religion: Muslim 10.205 6.774 0.136 −3.622 to 25.287
Religion: Atheist 0.921 3.322 0.782 −6.351 to 7.29
Religion: Other 2.139 5.9 0.718 −9.416 to 14.159
EQ-5D-5L VAS df Chi-sq p-value
# BL vs. Overall (joint) 3 1.63 0.654
IES
FH Breast −2.691 2.783 0.337 −8.768 to 2.934
FH Ovarian −2.838 4.625 0.541 −11.282 to 6.296
3 Months 0.541 1.688 0.749 −2.841 to 3.86
* 6 Months −3.533 1.724 0.042 −6.764 to −0.456
Age −0.009 0.1 0.93 −0.183 to 0.178
Income −1.53 0.895 0.091 −3.193 to 0.129
Marital Status −1.252 3.005 0.678 −7.493 to 4.494
Ethnicity 1.551 4.379 0.724 −6.956 to 10.635
Religion: Jewish 7.084 6.242 0.26 −5.696 to 18.636
Religion: Muslim −12.871 7.211 0.078 −25.685 to 2.043
* Religion: Atheist −8.159 3.377 0.018 −15.396 to −1.292
Religion: Other −3.833 6.028 0.527 −16.369 to 8.471
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IES df Chi-sq p-value
# BL vs. Overall (joint) 2 2.78 0.249
CWS
FH Breast Cancer 0.019 0.306 0.952 −0.616 to 0.639
FH Ovarian Cancer −0.138 0.535 0.797 −1.316 to 1.001
* 7 Days −0.73 0.182 <0.001 −1.096 to −0.399
* 3 Months −0.802 0.189 <0.001 −1.173 to −0.448
* 6 Months −0.775 0.195 <0.001 −1.16 to −0.358
Age −0.013 0.011 0.215 −0.035 to 0.009
Income −0.126 0.094 0.186 −0.325 to 0.065
Marital Status 0.335 0.329 0.311 −0.374 to 0.973
Ethnicity 0.585 0.44 0.187 −0.264 to 1.439
Religion: Jewish 1.375 0.71 0.056 −0.091 to 2.772
Religion: Muslim −1.073 0.737 0.149 −2.593 to 0.455
Religion: Atheist −0.491 0.365 0.182 −1.224 to 0.247
Religion: Other 1.157 0.647 0.078 −0.035 to 2.428
CWS df Chi-sq p-value
# BL vs. Overall (joint) 3 9.7 0.021
CRP Likert Scale
FH Breast Cancer 0.436 0.138 0.002 0.135 to 0.696
FH Ovarian Cancer 0.248 0.238 0.299 −0.207 to 0.748
* 7 Days −0.195 0.077 0.012 −0.349 to −0.041
3 Months −0.093 0.079 0.241 −0.251 to 0.068
6 Months −0.062 0.083 0.454 −0.237 to 0.111
Age −0.007 0.005 0.131 −0.017 to 0.002
Income 0.024 0.042 0.58 −0.071 to 0.107
Marital Status −0.032 0.148 0.83 −0.308 to 0.269
Ethnicity −0.089 0.197 0.654 −0.475 to 0.309
Religion: Jewish 0.173 0.321 0.592 −0.475 to 0.73
Religion: Muslim −0.179 0.332 0.59 −0.89 to 0.524
Religion: Atheist −0.115 0.164 0.486 −0.44 to 0.196
Religion: Other 0.127 0.292 0.665 −0.459 to 0.714
CRP Likert Scale df Chi-sq p-value
# BL vs. Overall (joint) 3 10.44 0.015
CRP VAS
FH Breast Cancer 6.455 4.416 0.148 −2.004 to 15.098
FH Ovarian Cancer −4.31 7.495 0.566 −19.607 to 9.766
7 Days −2.985 2.441 0.223 −7.692 to 2.013
3 Months 0.579 2.675 0.829 −4.12 to 5.918
6 Months −0.093 2.77 0.973 −5.488 to 5.632
Age −0.194 0.153 0.207 −0.487 to 0.084
Income 1.471 1.353 0.28 −1.386 to 4.059
Marital Status 0.794 4.727 0.867 −9.788 to 9.475
Ethnicity −9.792 6.261 0.121 −22.644 to 3.523
Religion: Jewish 3.429 10.238 0.739 −15.525 to 24.542
Religion: Muslim −0.805 10.561 0.939 −22.586 to 20.999
Religion: Atheist −6.437 5.263 0.225 −16.92 to 3.543
Religion: Other 1.36 9.434 0.886 −17.183 to 21.316
CRP VAS df Chi-sq p-value
# BL vs. Overall (joint) 3 2.51 0.474
DRS scale
FH Breast Cancer 1.741 12.287 0.888 −22.846 to 26.328
FH Ovarian Cancer 11.808 17.974 0.514 −24.157 to 47.773
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Age 0.208 0.437 0.636 −0.667 to 1.083
Income −0.001 <0.001 0.216 −0.001 to 0
Marital Status 24.362 14.121 0.09 −3.894 to 52.617
* Ethnicity 47.091 20.396 0.024 6.28 to 87.902
Religion: Jewish 24.538 25.272 0.336 −26.031 to 75.108
Religion: Muslim −11.145 32.366 0.732 −75.909 to 53.62
Religion: Atheist 10.411 16.022 0.518 −21.65 to 42.471
* Religion: Other 62.958 25.021 0.015 12.891 to 113.024
DRS Madalinska
FH Breast Cancer 0.118 0.093 0.21 −0.068 to 0.303
FH Ovarian Cancer 0.022 0.136 0.871 −0.25 to 0.294
Age 0.001 0.003 0.849 −0.006 to 0.007
* Income <0.001 <0.001 0.045 0 to 0
* Marital Status 0.247 0.107 0.025 0.033 to 0.46
Ethnicity 0.18 0.154 0.248 −0.129 to 0.488
Religion: Jewish 0.145 0.191 0.451 −0.238 to 0.528
Religion: Muslim −0.151 0.245 0.541 −0.641 to 0.34
Religion: Atheist 0.068 0.121 0.573 −0.173 to 0.31
* Religion: Other 0.642 0.189 0.001 0.263 to 1.021
HADS: Hospital Anxiety and Depression Scale questionnaire; IES: Impact of Events Scale questionnaire; CRP: Cancer
Risk Perception questionnaire; CWS: Cancer Worry Scale questionnaire; DRS: Decision Regret Satisfaction
questionnaire; VAS: Visual Analogue Scale; FH: family history; Coef: coefficient; Std. Err: standard error.
FH of breast cancer: positive versus negative (reference category); FH of ovarian cancer: positive versus negative
(reference category); 7 days: questionnaire scores at 7 days versus baseline (reference category); 3 months:
questionnaire scores at 3 months versus baseline (reference category); 6 months: questionnaire scores at 6 months
versus baseline (reference category); age: age in years (continuous variable); income: as a continuous variable,
but measured in £10,000 increments; marital status: cohabiting/living with partner/married (reference category)
versus divorced/separated/single/widowed; ethnicity: Caucasian (reference category) versus non-Caucasian;
religion Jewish: Christian (reference category) versus Jewish; religion Muslim: Christian (reference category)
versus Muslim; Atheist: Christian (reference category) versus atheist; religion other (Hindu, Buddhist, Sikh):
Christian (reference category) versus other. # BL vs. Overall (joint): Overall contrast test reflecting whether the mean
outcome scale values at each time point (7 days, 3 months, or 6 months) were jointly different from the baseline
for the whole group. This showed a significant decrease for CWS and CRP (Likert), but no significant change for
HADS, HADS anxiety, HADS depression, EQ-5D-5L, IES and CRP (VAS) outcomes jointly over time. * Variables of
statistical significance (p < 0.05).
In total, 85.5% strongly agreed and 13.2% agreed that their decision to undergo PGT/OC risk
stratification was the right decision and that they were satisfied with it. In total, 95% would make
the same choice again. Only 1.3% regretted their decision. Table 6 summarises responses to the
DRS questionnaire.
Table 6. Decision Regret Satisfaction questionnaire responses according to individual questionnaire items.
Questionnaire Items
Questionnaire Responses
Strongly
Disagree Disagree
Neither Agree
nor Disagree Agree
Strongly
Agree
% N % N % N % N % N
It was the right decision 0 0/76 0 0/76 1.32 1/76 13.16 10/76 85.53 65/76
I regret the choice that
was made 80.26 61/76 14.47 11/76 2.63 2/76 1.32 1/76 1.32 1/76
I would go for the same choice
if I had to do it over again 0 0/76 1.32 1/76 3.95 3/76 13.16 10/76 81.58 62/76
The choice did me a lot of harm 89.33 67/75 8 6/75 2.67 2/75 0 0/75 0 0/75
The decision was a wise one 1.32 1/76 0 0/76 2.63 2/76 13.16 10/76 82.89 63/76
I am satisfied with the decision
I have made 0 0/76 0 0/76 1.32 1/76 13.16 10/76 85.53 65/76
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A FH of BC (p = 0.034) but not OC (p = 0.20) was negatively associated with QOL. Having a FH
of OC was not associated with an increase in OC worry or general cancer risk perception.
However, women with a FH of BC perceived themselves to be at higher cancer risk (p = 0.002)
but did not have increased OC worry.
Results from contrast tests assessing the joint effect of between-group and within-group differences
in various outcomes over six months compared to baseline are shown in Table 7. There was no
statistically significant between-group difference for groups ‘with’ and ‘without’ a FH of OC for HADS
total/HADS depression/HADS anxiety/QoL/distress/OC worry/general cancer risk perception over
time. There was no statistically significant within-group difference for groups ‘with’ and ‘without’ a FH
of OC for HADS total/HADS anxiety/QoL/general cancer risk perception over six months. However,
there was a statistically significant within-group difference for individuals ‘without’ a FH of OC but not
‘with’ a FH of OC for HADS depression (p = 0.003, p = 0.866, respectively), distress (p = 0.043, p = 0.524
respectively) and OC worry (p ≤ 0.001, p = 0.582, respectively) over six months. Viewing the contrast
tests together in combination with the linear random-effects mixed-model outputs would suggest a
small increase in HADS depression scores not of clinical significance and a decrease in distress and OC
worry over six months for the ‘without’ a FH of OC group.
Table 7. Contrast tests for between-group and within-group analyses over time.
HADS total df Chi-sq p-value CRP Likert scale df Chi-sq p-value
Event#Group Event#Group
BL vs. 7 Days (joint) 1 0.43 0.51 BL vs. 7 Days (joint) 1 1.16 0.281
BL vs. 3 Months (joint) 1 0.07 0.797 BL vs. 3 Months (joint) 1 2.7 0.101
BL vs. 6 Months (joint) 1 0.13 0.719 BL vs. 6 Months (joint) 1 0.78 0.378
BL vs. Overall (joint) 3 1.05 0.788 BL vs. Overall (joint) 3 2.8 0.423
Event|Group Event|Group
BL vs. Joint|OC FH− 3 7.08 0.07 BL vs. Joint|OC FH− 3 6.69 0.083
BL vs. Joint|OC FH+ 3 2.57 0.463 BL vs. Joint|OC FH+ 3 6.59 0.086
HADS anxiety df Chi-sq p-value CRP VAS df Chi-sq p-value
Event#Group Event#Group
BL vs. 7 Days (joint) 1 0.62 0.431 BL vs. 7 Days (joint) 1 2.23 0.135
BL vs. 3 Months (joint) 1 <0.01 0.972 BL vs. 3 Months (joint) 1 0.51 0.477
BL vs. 6 Months (joint) 1 0.04 0.849 BL vs. 6 Months (joint) 1 1.1 0.294
BL vs. Overall (joint) 3 1.05 0.79 BL vs. Overall (joint) 3 5.63 0.131
Event|Group Event|Group
BL vs. Joint|OC FH− 3 4.39 0.222 BL vs. Joint|OC FH− 3 2.37 0.5
BL vs. Joint|OC FH+ 3 3.51 0.319 BL vs. Joint|OC FH+ 3 4.37 0.224
HADS depression df Chi-sq p-value EQ-5D-5L UK score df Chi-sq p-value
Event#Group Event#Group
BL vs. 7 Days (joint) 1 0.03 0.869 BL vs. 7 Days (joint) 1 2.36 0.125
BL vs. 3 Months (joint) 1 <0.01 0.971 BL vs. 3 Months (joint) 1 2.44 0.118
BL vs. 6 Months (joint) 1 0.91 0.339 BL vs. 6 Months (joint) 1 2.25 0.133
BL vs. Overall (joint) 3 1.18 0.759 BL vs. Overall (joint) 3 3.66 0.3
Event|Group Event|Group
* BL vs. Joint|OC FH− 3 14.18 0.003 BL vs. Joint|OC FH− 3 7 0.072
BL vs. Joint|OC FH+ 3 0.73 0.866 BL vs. Joint|OC FH+ 3 1.11 0.774
IES Score df Chi-sq p-value EQ-5D-5L VAS df Chi-sq p-value
Event#Group Event#Group
BL vs. 3 Months (joint) 1 1.09 0.297 BL vs. 7 Days (joint) 1 0.64 0.425
BL vs. 6 Months (joint) 1 0.01 0.93 * BL vs. 3 Months (joint) 1 6.47 0.011
BL vs. Overall (joint) 2 1.3 0.523 BL vs. 6 Months (joint) 1 1.4 0.237
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Event|Group BL vs. Overall (joint) 3 6.74 0.081
* BL vs. Joint|OC FH− 2 6.31 0.043 Event|Group
BL vs. Joint|OC FH+ 2 1.29 0.524 BL vs. Joint|OC FH− 3 3.89 0.273
CWS Score df Chi-sq p-value
Event#Group
BL vs. 7 Days (joint) 1 0.99 0.32
BL vs. 3 Months (joint) 1 0.25 0.615
BL vs. 6 Months (joint) 1 0.18 0.675
BL vs. Overall (joint) 3 1 0.802
Event|Group
* BL vs. Joint|OC FH− 3 26.92 <0.001
BL vs. Joint|OC FH+ 3 1.95 0.582
BL: baseline; FH: family history; HADS: Hospital Anxiety and Depression Scale questionnaire; IES: Impact of
Events Scale questionnaire; CRP: Cancer Risk Perception questionnaire; CWS: Cancer Worry Scale questionnaire;
VAS: Visual Analogue Scale. ‘Group’ refers to either participants with a family history of ovarian cancer (OC FH+
group) or no family history of ovarian cancer (OC FH− group). ‘Event#Group’ refers to the group–time interaction,
which reflects the ‘between-group’ (OC FH+ vs. OC FH−) difference over time. BL vs. 7 days (joint), BL vs. 3 months
(joint), and BL vs. 6 months (joint) reflect whether the mean between-group difference at each time point (7 days,
3 months, or 6 months) was different from baseline. BL vs. Overall (joint) reflects whether the mean between-group
differences at each time point (7 days, 3 months, or 6 months) were jointly different from the baseline between-group
difference. Event|Group refers to the group–time interaction, which reflects the ‘within-group’ difference over
time. BL vs. Joint |OC FH− reflects whether the mean outcome scale value at each time point (7 days, 3 months,
or 6 months) was jointly different from the baseline within the ovarian cancer family history negative group. BL vs.
Joint |OC FH+ reflects whether the mean outcome scale value at each time point (7 days, 3 months, or 6 months) was
jointly different from the baseline within the ovarian cancer family history positive group. * Statistical significance
(p < 0.05).
3. Discussion
This is the first unselected population-based, prospective cohort study recruiting participants without
cancer history in self/family, evaluating the feasibility of personalised lifetime OC risk stratification followed
by offering risk management options. Data suggest that OC risk stratification using genetic/non-genetic
(epidemiological/hormonal) factors in general population women is feasible and acceptable.
The 85% uptake of PGT and OC risk stratification suggests high acceptability, similar to previously
published data indicating putative 85% uptake of PGT (n = 734/829 in a survey study assessing
attitudes of a general population of women to unselected PGT and risk-stratified OC screening [15,16].
Findings are also similar to data showing the high acceptability of unselected BRCA testing in AJ
populations (up to 88% uptake) [17]. The 85%–98% overall satisfaction we found with PGT is similar
to rates reported with population-based BRCA testing in AJ populations [9,12].
Data from unselected BRCA testing in the AJ population [9,10,14,18,19] show acceptability/
feasibility/effectiveness/cost effectiveness/lack of detrimental impact on psychological health/QoL,
and support the concept of population-based BRCA testing in Jewish populations. However, these
inferences cannot be directly generalized to a non-Jewish general population. Our findings of
overall time effect contrast tests showing levels of anxiety/depression/QoL/distress not being jointly
different from baseline values but a significant reduction in OC-specific worry/general cancer risk
perception following OC risk stratification are reassuring. Small changes in scores observed in
some outcomes at individual time points were not clinically meaningful. While larger studies are
warranted, these initial findings concur with short-/long-term outcome data following unselected BRCA
testing in AJ populations [9,13] and are similar to findings amongst high-risk individuals undergoing
clinical criteria-based genetic testing [20–22]. In total, 25.5% of our cohort was non-Caucasian
(13.7% Asian). We found no difference in psychological health/QoL outcomes amongst non-Caucasians
versus Caucasians. More research is required for understanding the role of various risk factors
in non-Europeans.
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Our online DA was successfully completed by women from a wide range of ages (18–85),
education levels, and ethnicities, with high levels (92.2%) of satisfaction. Women who used the optional
telephone helpline reported higher levels of worry/upset when viewing the DA. In total, 75% of women
using the telephone helpline did so for technical DA assistance. All went on to successfully view the
online DA. The telephone helpline appears to have been used as a source of emotional/technical support,
emphasising the importance/need for a telephone helpline as an adjunct to online web applications to
facilitate access/decision making for PGT/OC risk stratification. That one volunteer consented despite her
DA score (−1) indicating she was “leaning against taking part”, highlights that whilst decision aids are
adjuncts aiding decision making, individuals retain ultimate autonomy. While we showed the feasibility
of using an online DA and helpline approach for PGT, this has not been compared in randomised trials to
more standard/established methods (face-to-face/telephone-based/DVD-assisted counselling).
Our study strengths include population-based recruitment in a non-Jewish, ethnically diverse
general population. We engaged and worked with primary care networks prior to study commencement.
They helped increase awareness of this study, identify eligible women and facilitate recruitment.
Engagement with primary care would be vital for the implementation of any national population-based
model for PGT/OC risk stratification. Other advantages include a good questionnaire response rate,
ranging from 99% (baseline) to 75% (six months follow up).
Limitations include the small sample size, lack of long-term follow up on QoL/psychological
health/health behaviours. Additionally, this study was non-randomised and a control arm
(without genetic testing) to compare any change in outcomes was lacking. However, the high-risk
individual identified did opt for appropriate screening and preventive interventions to reduce OC/BC
risk. Lack of intermediate-risk women identified probably reflects the small sample size.
In our cohort, 45% vs. 40% [23] of the UK general population had a university level education;
7% vs. 15% [23] were current smokers; 64% vs. 32% [23] ate the recommended ≥5 portions of
fruit/vegetables daily; 78% vs. 64% [23] were physically active over the last month; median total
household income was >£50,000 vs. £29,000 in the UK general population [23]. Higher income,
education levels and healthy lifestyle behaviour in our study participants compared to the UK’s general
population may indicate a London bias. The income/education levels/lifestyle choices are similar to
those of the UK Jewish population [9,17]. Significant associations of some study outcome variables seen
with demographic variables of income/age are consistent with observations from population-based
data reported in other population cohorts.
Precision prevention is a prevention strategy incorporating individual variation in genetic,
epi-genetic and non-genetic (e.g., environment, hormonal, lifestyle, behavioural) risk factors.
This comprises primary prevention to prevent occurrence of disease and, secondary prevention for
screening/early detection of pre-symptomatic disease. Next-generation sequencing technologies,
falling costs and advances in computational bioinformatics makes personalised risk-stratified
prevention feasible. Improvements in the precision of risk estimation, genetic understanding of
disease and increasing awareness offers an opportunity to apply this knowledge and technology at a
broad population scale to make an important shift in health care towards disease prevention. Over 50%
of OCs occur in 9% of the population, which is at >5% OC risk [4]. This provides a huge opportunity
for population stratification for precision prevention. Identification of unaffected women at increased
risk offers opportunities for risk-stratified prevention to reduce cancer burden. Women at increased
OC risk can opt for risk-reducing salpingo-oophorectomy (RRSO) to prevent tubal cancer/OC [24],
now advocated at >4–5% lifetime OC risk [25–27].
Access to and uptake of testing for CSGs remains restricted. Only a small proportion of at-risk
BRCA carriers have been identified [7,8]. Our approach offers opportunities to maximise pathogenic
variant identification and population stratification for OC prevention. While recent data suggest that
population-based genetic testing for OC/BC gene pathogenic variants could be cost effective in general
population women [11], additional research including general population implementation studies are
needed to address knowledge gaps before considering this. Additional looked for findings have recently
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been offered and returned following post hoc sequencing and/or analysis of some large genomic study
cohorts. These studies would enable evaluation of CSG pathogenic variant carriage rates. However,
this would not address in a prospective unbiased fashion key questions around the (i) logistics of
population testing; (ii) information giving, a priori informed consent, and uptake of testing; (iii) uptake
of preventive options. This ‘bolt-on’ paradigm of returning additional ‘secondary findings’ cannot be
equated to prospective uptake of testing CSGs in an unselected unaffected population.
A prospective, Canadian cohort study offering BRCA1/BRCA2 testing to unselected men/women
(The Screen Project) is ongoing. The study is evaluating the feasibility of a direct-to-consumer approach,
satisfaction, OC worry, prevalence of BRCA1/BRCA2 pathogenic variants and the number of OCs/BCs
prevented. Results from our feasibility study would inform the development of a larger UK-wide
study that implements PGT/OC risk-stratified prevention. An important challenge is identifying
optimum implementation pathways. It is likely that different context-specific models are needed for
various health care systems internationally. Risk assessment pathways could be established through a
community/primary care-based approach outside the traditional hospital-based genetics clinic model.
A key issue that needs resolving is a system for monitoring/managing VUS. Commissioning/funding
of a system where laboratory reports can be reviewed and re-issued in light of new evidence is needed.
A framework/structure for data management and legal and regulatory protections will also need to
be established.
4. Materials and Methods
4.1. Design
A multicentre, prospective cohort, feasibility study (ISRCTN:54246466). Inclusion criteria:
women ≥18 years. Exclusion criteria: history of ovarian/tubal/primary peritoneal cancer or previous
genetic testing for OC CSGs.
4.2. Recruitment
Recruitment was by self-referral. Study information/leaflets were made available through
North-East London primary care practices. Interested volunteers received a detailed participant
information sheet and access to an online DA prior to consent to genetic testing/participation. All had
access to use an ‘optional’ telephone helpline for support/advice/queries. The helpline was manned
by a doctor/research nurse experienced in cancer genetic risk assessment/management. Individuals
deciding to undergo PGT/OC risk assessment consented. Decliners were asked to provide information
on factors affecting decision making.
4.3. Decision Aid (DA)
A bespoke web-based DA was developed, enabling potential participants to make an informed
decision on whether they wish to determine their OC risk and undergo PGT/OC risk assessment [16,28].
The DA (Table S2) included information on OC, genetic testing and the PROMISE programme,
followed by ten questions/items on potential advantages/disadvantages of learning about OC risk.
Responses were rated according to two different 3-point Likert scales. Individual questions were
scored according to responses ((a) 1 = in favour of taking part, −1 = against taking part, 0 = neither
in-favour or against taking part; or (b) 1 = agree, −1 = disagree, 0 = unsure). Sum of all questions/items
scores taken together ranged from −10 to 10. Women with total scores between −10 and −1 were
considered “leaning against taking part”, 0–5 “undecided”, and 6–10 “leaning towards taking part”.
4.4. Genetic Analysis
Genetic testing involved next-generation sequencing of BRCA1/BRCA2/RAD51C/RAD51D/BRIP1
genes and 30 GWAS-validated OC SNPs. Pathogenic variants detected were reconfirmed in an
NHS laboratory.
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4.5. Risk Model
Epidemiological/hormonal/reproductive data affecting OC risk collected at baseline
(age/OC-FH/body mass index (BMI)/tubal ligation/hormone-replacement therapy (HRT)/oral
contraceptive pill (OCP) use/endometriosis/parity) were combined with genetic information in a
risk prediction algorithm (RPA) to provide a personalised predicted lifetime OC risk (till 80 years).
Model validation (personal communication) [5] was undertaken in prospective datasets and cancers
accrued in the UK OC screening trial cohorts [5,29,30]. Following RPA assessment, all participants
were stratified into risk categories by lifetime OC risk (low risk: <5%; intermediate risk: ≥5%–<10%;
high risk: ≥10%).
4.6. Test Result Management
High/intermediate-risk (and an equivalent number of randomly selected low-risk) individuals
received their result at a face-to-face post test risk stratification counselling appointment.
Identified pathogenic/likely pathogenic variant heterozygotes were referred to an NHS regional genetics
clinic for confirmatory testing and to established NHS risk management services. Other low-risk
individuals received results via post. Variants of uncertain significance (VUS) results were not returned.
4.7. Assessment of Demographics, Outcomes and Follow Up
Sociodemographic, family history, perceived risk/limitation (4-point Likert scale), telephone
helpline and DA evaluation data were collected using customised questionnaires. Anxiety and
depression were assessed with the Hospital Anxiety and Depression Scale (HADS) [31]. Distress was
assessed using the Impact of Events Scale (IES) [32]. General cancer risk perception was measured
by two items. Comparative risk: ‘Compared with other people of your age/sex, do you think your
chances of getting cancer in your life are: much-lower, lower, about-the-same, higher, much-higher?’
An additional risk item: ‘On a scale from 0 to 100, where 0 is no chance at all and 100 is absolutely
certain, what are the chances you will get cancer sometime during your lifetime?’. OC worry was
assessed by the Cancer Worry Scale (CWS) [33]. Generic QoL was measured with the EQ-5D-5L
questionnaire [34]. Satisfaction and regret were measured by the Decision Regret Satisfaction Scale
(DRS) and one additional 5-point Likert scale item, ‘I am satisfied with the decision I have made’ [35].
Smoking, diet and physical activity were evaluated. Data were gathered at baseline following consent
and post results delivery (seven days/three months/six months).
4.8. Statistical Analysis
Descriptive statistics were used for baseline characteristics/telephone helpline/DA/follow-up
questionnaire data. The Wilcoxon rank sum test and Fisher’s exact test evaluated differences in means
and proportions correspondingly.
As outcome data from the HADS/EQ-5D-5L/IES/CWS/CRP/DRS questionnaires were collected
over multiple time points, linear random-effects mixed models were used to allow for individual
baseline-level variability. Each scale was analysed, with the outcome as a continuous response
variable. Models included a group effect and time effect. Models were adjusted for FH of
OC/BC (positive/negative), age, income (in £10,000 increments), marital status (cohabiting/living with
partner/married versus divorced/separated/single/widowed), ethnicity (Caucasian versus non-Caucasian)
and religion (Muslim/Christian/Jewish/no religion/other (Hindu/Buddhist/Sikh)). Linear random-effects
mixed models were used to model trends in DA scores for participants viewing the DA on multiple occasions.
Post modelling, three contrast tests were considered (each on three degrees of freedom).
We assessed (a) overall time effects, i.e., whether the overall mean values at seven days, three
months and six months from baseline were jointly different from the baseline level, (b) between-group
differences over time (whether the mean group differences between those ‘with’ and ‘without’ a FH of
OC at seven days, three months and six months from baseline were jointly different from the baseline
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level) and (c) within-group differences over time (whether mean values at seven days, three months
and six months from baseline were jointly different from the baseline level within the groups ‘with’ and
‘without’ FH of OC). Statistical analysis used Stata-13.0 (Stata-Corp-LP, TX, https://www.stata.com/)
and R version 3.5.1 (https://www.r-project.org/).
5. Conclusions
Our current health care systems remain primarily centred on improving disease diagnosis and
treatment rather than prevention. Prevention of chronic disease, cancer being the second most common
cause, is a major challenge for our health systems. PGT and personalised OC risk stratification can spur CSG
detection and maximise precision prevention to reduce OC burden. We have shown that population-based
personalised OC risk stratification is feasible and acceptable, has high satisfaction, reduces cancer
worry/risk perception, and does not negatively impact on psychological health/quality of life. Further
research and implementation studies evaluating the impact, clinical efficacy, long-term psychological, and
socioethical consequences and cost effectiveness of this strategy are needed. This includes evaluation
through large implementation studies of real-world health outcomes. Future implementation of such
a strategy will require varying levels of workforce expansion/upskilling and reorganisation of health
service infrastructure covering aspects of genetic testing and downstream care including screening and
prevention pathways. PGT is an exciting and evolving field and personalised OC risk stratification offers
a new paradigm for precision prevention in OC.
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occasions; Table S4: Linear random-effects mixed models for trends in decision aid scores in participants viewing
the decision aid on multiple occasions; Figure S1: Distributions of the remaining lifetime ovarian cancer risks
given by different model versions.
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